Studies

  1. COVID vaccine response in IBD on different drugs

  2. Upadacitinib in UC induction and maintenance

  3. Infliximab vs conventional therapy in pediatric CD

  4. Surgical closure, mainly with glue injection and anti-tumour necrosis factor α, in perianal CD

  5. Safety and tolerability of spesolimab in UC

  6. Ustekinumab vs adalimumab in CD